Micro-Tech (Nanjing) Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Nanwei Medical Technology Co., Ltd. was founded in 2000. The company is mainly engaged in the research and development, manufacturing, and sales of minimally invasive medical devices. Adhering to the principle of "serving clinical practice with technology and innovation", we are committed to providing high-quality products and services to global medical institutions, helping to improve medical standards, reduce patient suffering, and reduce medical costs worldwide. After nearly 20 years of innovative development, the company has gradually transitioned from a single product of non vascular stents to three major technology platforms, with a focus on the domestic market to a dual wheel drive in the domestic and international markets. It has become a leading company in the field of minimally invasive diagnosis and treatment with high research and innovation strength, core product competitive advantages, and rapid growth in performance. The company's scientific research and innovation strength has been recognized by authority. The National Science and Technology Award is the highest national science and technology award approved by the State Council. The company has won two second prizes of the National Science and Technology Progress Award, and its subsidiary's R&D personnel have won one second prize of the the State Technological Innovation Award. It is one of the few enterprises in the industry that has won national science and technology awards for many times. In addition, the company has undertaken 3 national level scientific research projects, owned 36 domestic and foreign invention patents, obtained 28 Class III medical device registration certificates, and 45 Class II medical device registration certificates. We have successively won honorary titles such as Key High tech Enterprise of the National Torch Program, Small and Medium sized Science and Technology Enterprise of Jiangsu Province, Key R&D Institution of Jiangsu Province, and Private Science and Technology Enterprise of Jiangsu Province. The company's core products have competitive advantages. The company's main products include two main product lines: endoscopic minimally invasive diagnostic and treatment equipment and tumor ablation equipment. The newly developed endoscopic optical coherence tomography system (EOCT) has been awarded the company's endoscopic minimally invasive diagnostic and treatment equipment for clinical diagnosis and treatment of digestive and respiratory diseases, including six sub series of products, providing a systematic solution for endoscopic diagnosis and treatment, The portable 125I radiotherapy particle stent technology has been rated as the world's first; Tumor ablation product equipment is mainly used for precise microwave ablation of tumors, and has become one of the mainstream medical methods in the field of liver cancer treatment; EOCT is mainly used in conjunction with endoscopy, which can be used for early cancer screening and surgical planning, and is expected to develop into the main means of "non-invasive optical biopsy". Development of dual wheel drive companies in domestic and international markets. In the domestic market, the company's endoscopic diagnosis and treatment technology product line has played a strong import substitution role, effectively reducing the cost of endoscopic diagnosis and treatment, and reducing the burden on patients. The company's products have been sold to more than 2900 hospitals nationwide, with a coverage rate of over 55% for tertiary hospitals. In terms of foreign markets, the company has subsidiaries in the United States and Germany, and multiple products have passed FDA approval and EU CE certification. The products are exported to more than 70 countries and regions, including developed countries such as the United States, Germany, Canada, and Japan. The company's performance is growing rapidly. From 2016 to 2018, the annual compound growth rate of the company's sales revenue reached, with a growth rate far higher than the industry level. In order to maintain sustained growth, the company has strategically laid out an EOCT system with cutting-edge technology, which is the second globally approved product by the US FDA. Currently, clinical research is being conducted at institutions such as the Mayo Clinic and Stanford University Hospital Medical Center in the US, and it is an important growth point for the company's future business development. In the future, the company will continue to focus on the core ability of transforming medical innovation achievements, continuously expand and strengthen the existing three product lines, and timely enter new minimally invasive diagnosis and treatment fields in the future, striving to become a global leading enterprise in the field of minimally invasive diagnosis and treatment. |
| Headquarter | Nanjing |
| Establish Date | 5/10/2000 |
| Listed Code | 688029.SH |
| Listed Date | 7/22/2019 |
| Chairman | Long Xiaohui. |
| CEO | Cold Derong. |
| Website | www.micro-tech.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
